Related Experiment Videos
[Bioaccessibility of diazepam administered as Valium and Valaxon tablets]
Ugeskrift for Laeger
|January 2, 1989
Summary
Bioaccessibility of diazepam (Valaxon vs. Valium) showed no significant difference in healthy volunteers. Pharmacokinetic studies offer valuable clinical insights and are feasible in hospital settings.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Bioavailability Studies
Background:
- Diazepam is a widely prescribed benzodiazepine.
- Understanding diazepam bioaccessibility is crucial for therapeutic efficacy.
- Comparing different formulations ensures consistent patient outcomes.
Purpose of the Study:
- To investigate and compare the bioaccessibility of diazepam from Valaxon and Valium tablet formulations.
- To assess the clinical relevance of bioaccessibility differences between generic and brand-name diazepam.
Main Methods:
- A double-blind, cross-over study design was employed.
- Twelve healthy volunteers participated in the investigation.
- Bioaccessibility of diazepam was measured after administration of both formulations.
Main Results:
- No statistically significant difference was observed in the bioaccessibility of diazepam between Valaxon and Valium tablets.
- The pharmacokinetic profiles of both formulations were comparable in the study population.
Conclusions:
- Diazepam bioaccessibility is consistent between Valaxon and Valium formulations.
- Pharmacokinetic studies are valuable for clinical decision-making and are practical within hospital departments.